Avalo Therapeutics, Inc. (AVTX)
$
4.84
-0.15 (-3.10%)
Key metrics
Financial statements
Free cash flow per share
-4.9749
Market cap
52.4 Million
Price to sales ratio
118.8335
Debt to equity
0
Current ratio
22.6075
Income quality
-0.7165
Average inventory
0
ROE
1.0636
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics to address unmet clinical needs across immunology, immuno-oncology, and rare genetic diseases. The company is actively developing AVTX-002, a fully human anti-LIGHT monoclonal antibody currently undergoing a Phase II clinical trial aimed at treating non-eosinophilic asthma, as well as inflammatory bowel diseases, which include moderate to severe Crohn's disease and ulcerative colitis. Additionally, AVTX-002 is also in a Phase III clinical trial for treating COVID-19 acute respiratory distress syndrome. Furthermore, Avalo is working on AVTX-007, a fully human anti-IL-18 monoclonal antibody, which is currently in a Phase I clinical trial for Still's disease, encompassing adult-onset Still's disease and systemic juvenile idiopathic arthritis. The company is also advancing its pipeline for rare genetic diseases with AVTX-801, a D-galactose substrate replacement therapy in Phase III clinical trials for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG, and AVTX-803, an L-fucose substrate replacement therapy for the treatment of LADII, or SLC35C1-CDG. Recently, the company reported depreciation and amortization expenses of $169,000.00 reflecting the wear and tear of its assets. The EBITDA is -$68,343,000.00 a key indicator of the company's operational profitability, and the financial data pertains to the fiscal year 2024. The weighted average number of diluted shares outstanding is 10,784,037.00 reflecting potential dilution effects. Moreover, the company earned an interest income of $0.00 showcasing its financial investments. In the competitive landscape, Avalo Therapeutics, Inc. is classified as a small-cap player, with a market capitalization of $52,405,584.00. The stock is affordable at $4.84 making it an attractive option for budget-conscious investors. Notably, the stock has a low average trading volume of 75,698.00 indicating lower market activity. As a key player in the Biotechnology industry, Avalo contributes significantly to the overall market landscape, driving innovation and growth in the Healthcare sector.
Is Avalo Therapeutics, Inc. (AVTX) a good investment?
Investing in Avalo Therapeutics, Inc. (AVTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Avalo Therapeutics, Inc. (AVTX)'s stock forecast?
Analysts predict Avalo Therapeutics, Inc. stock to fluctuate between $3.39 (low) and $16 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avalo Therapeutics, Inc.'s market capitalization?
As of 2025-07-01, Avalo Therapeutics, Inc.'s market cap is $52,405,584, based on 10,827,600 outstanding shares.
How does Avalo Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Avalo Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Avalo Therapeutics, Inc. (AVTX) stock?
To buy Avalo Therapeutics, Inc. (AVTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AVTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Avalo Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Avalo Therapeutics, Inc. stock ever split?
Avalo Therapeutics, Inc.'s last stock split was 1:240 on 2023-12-29.
How did Avalo Therapeutics, Inc. perform in the last earnings report?
Revenue: $441,000 | EPS: -$4.32 | Growth: -96.20%.
Where can I find Avalo Therapeutics, Inc.'s investor relations reports?
Visit https://www.avalotx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avalo Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Avalo Therapeutics, Inc. stock?
All-time high: $9,331.20 (2021-09-01) | All-time low: $3.39 (2025-05-14).
What are the key trends affecting Avalo Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
9 days ago
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:
globenewswire.com
14 days ago
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
globenewswire.com
a month ago
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.
globenewswire.com
2 months ago
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025.
globenewswire.com
2 months ago
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.
globenewswire.com
3 months ago
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
benzinga.com
3 months ago
On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases.
globenewswire.com
3 months ago
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md.
globenewswire.com
4 months ago
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March.
globenewswire.com
5 months ago
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.
See all news
